Drugs / Human recombinant growth hormone
Human recombinant growth hormone
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00182169 | Jul 1997 → Jun 2005 | heart failure | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00005112 | — | cystic fibrosis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01614171 | Dec 2013 → Dec 2015 | osteoporosis-pseudoglioma syndrome | University of Maryland, Baltimore | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human recombinant growth hormone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01614171 ↗ |
| Modality | Protein / enzyme biologic | “human recombinant growth hormone” NCT00005112 ↗ |